Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies

NCT02017613 ↗

Phase 1 Completed 35 enrolled Rhizen Pharmaceuticals SA

NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the safety and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with hematologic malignancies.

Timeline

Start: 2013-11
Primary completion: 2016-05
Completion: 2016-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tenalisib	Small molecule	25 mg	Oral

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies

Summary

Timeline

Drugs

Indications